This fortnight's issue is dominated by a significant wave of FDA de novo-style Class II classification orders spanning AI/ML radiology software, neurological stimulators, orthopedic implants, diagnostics and more — each establishing new special-controls pathways that will shape 510(k) strategies for years to come. On the UK side, MHRA has refreshed its Innovation Accelerator offering and updated borderline-product guidance, while the June Safety Roundup and two batches of Field Safety Notices demand attention from post-market teams. Regulatory leaders should also note the FDA's revocation of three COVID-19 IVD EUAs and a high-profile warning-letter resolution involving a consumer wellness wearable — both carrying lessons for lifecycle management.
FDA Classifies Radiological ML-Based Quantitative Imaging Software with Predetermined Change Control Plan into Class II
FDA · US
This is one of the most strategically significant classifications in the batch. By establishing Class II (special controls) for AI/ML quantitative imaging software that incorporates a Predetermined Change Control Plan (PCCP), FDA has created a defined regulatory pathway for adaptive AI devices — a question that has hung over the sector for years. Manufacturers developing or planning radiology AI products must now align their PCCP documentation and 510(k) submissions to these special controls. This also signals FDA's intent to make PCCP a mainstream, rather than exceptional, mechanism.
Read the source →FDA Classifies Monitor for Opioid-Induced Impairment of Oxygenation into Class II
FDA · US
With opioid safety remaining a major public-health priority, FDA's classification of this novel monitoring device into Class II via special controls opens a clear 510(k) route for competitors and follow-on products. Anesthesiology device makers should review the special controls language carefully — performance testing, clinical data and labelling requirements will define the evidence bar for future submissions. Effective 30 June 2026.
Read the source →FDA Classifies Medial Knee Implanted Shock Absorber into Class II
FDA · US
Orthopedic implant manufacturers targeting knee OA patients should take note: this classification establishes the first formal special-controls framework for medial knee shock absorbers, a category that has operated without a clear predicate landscape. Class II status means a 510(k) route is now available, but the specific performance and clinical evidence required by the special controls will set the competitive entry bar. Teams should obtain and analyse the full Federal Register order before planning regulatory strategy.
Read the source →FDA Classifies SARS-CoV-2 Serology Test into Class II — Alongside Revocation of Three COVID-19 IVD EUAs
FDA · US
Two complementary actions define the post-pandemic IVD landscape. First, SARS-CoV-2 serology tests now have a permanent Class II classification with special controls, replacing the EUA framework and requiring 510(k) clearance for continued marketing. Second, FDA has formally revoked EUAs for BD, InBios and Roche COVID-19 diagnostics (effective 24 February 2026 — now published). IVD manufacturers still relying on EUA status for any COVID-related test must urgently assess their transition to permanent clearance or face market withdrawal. This dual development is a textbook lifecycle-management case study.
Read the source →FDA Classifies Computerized Behavioral Therapy Device for Fibromyalgia Symptoms into Class II
FDA · US
Digital therapeutics (DTx) continues to gain formal regulatory footing. This classification for a Software as a Medical Device (SaMD) delivering behavioral therapy confirms FDA's willingness to apply the Class II special-controls model to software-only interventions in neurological/pain indications. DTx developers and their regulatory affairs teams should extract the special controls to benchmark clinical evidence, cybersecurity and usability requirements against their own pipeline. The precedent also has implications for EU MDR classification of comparable products.
Read the source →MHRA Updates Borderline Products Guidance and Refreshes Innovation Accelerator
MHRA · UK
Two MHRA publications this fortnight are directly relevant to product strategy. The updated borderline-products guidance clarifies how MHRA determines whether a product falls under medical device regulations — critical for manufacturers of combination products, digital health tools, and novel materials where classification is contested. Simultaneously, MHRA has refreshed its Innovation Accelerator programme pages, which provide SMEs and innovative developers with access to pre-submission scientific advice and regulatory signposting. For small and mid-sized manufacturers, early engagement with the Innovation Accelerator can substantially de-risk UKCA submissions and shorten time-to-market.
Read the source →MHRA June 2026 Safety Roundup and Field Safety Notices (15–19 & 22–26 June)
MHRA · UK
Post-market surveillance teams must review three overlapping UK safety publications this fortnight: the MHRA June 2026 Safety Roundup covering medicines and devices, and two consecutive weekly Field Safety Notice (FSN) compilations. For manufacturers with products on the UK market, FSNs from peer companies provide important vigilance intelligence and may trigger internal signal assessments. The Safety Roundup is also a useful resource for QA teams updating risk management files or preparing periodic safety update reports under UK MDR 2002 obligations.
Read the source →FDA Drops Whoop Warning Letter After Blood Pressure Feature Changes — A Wellness-Device Compliance Lesson
INDUSTRY · GLOBAL
The resolution of FDA's warning letter against Whoop over its blood pressure 'insights' feature offers a valuable compliance case study for any manufacturer integrating wellness or lifestyle claims into connected devices. FDA's concerns centred on whether the feature crossed the line into an uncleared medical device function. Whoop's remediation — modifying the feature to satisfy FDA's wellness-device framework — demonstrates the practical importance of intended-use documentation, claim language, and proactive FDA engagement. Teams developing wearables or digital health apps with physiological monitoring capabilities should use this case to audit their own intended-use statements and marketing materials.
Read the source →